title: Persistence and titer changes of rubella virus antibodies in primiparous women who had been vaccinated with strain RA 27/3 in junior high school.
abstract: Taiwan's rubella vaccination program was launched in 1986; each schoolgirl in the third grade of junior high school received one dose of rubella (RA 27/3) vaccine. We reviewed the results of 14,090 prenatal rubella tests for primiparas from three areas of Taiwan during 2002 to 2008 to investigate seronegativity rates and titer changes. In all primiparous women, the average rubella virus seronegativity rate was 6.5% (95% confidence interval [95% CI], 6.1 to 6.9%), and the average rubella virus antibody titer was 65.9 IU/ml (95% CI, 64.7 to 67.1 IU/ml). There were 1,220 women (8.7%) with weakly positive antibody titers (10 to 20 IU/ml). The rubella virus seronegativity rates, which ranged from 5.4 to 9.7%, did not exhibit a linear trend from 9 to 22 years after vaccination (P = 0.201); in contrast, a significant trend appeared in the average rubella virus IgG titer (P = 0.003), dropping from 69.9 IU/ml in the 9th year after vaccination to 54.8 IU/ml in the 22nd year. The mean annual antibody decay rate was -0.77 IU/ml. This study reveals that the level of rubella virus antibodies declined slowly in women of childbearing age who were vaccinated with RA 27/3 at junior high school age. The number of women who were seronegative or had weakly positive antibody titers was still high (15.2%). Therefore, in countries that implement a single-dose regimen in children or teenagers, it should remain an important policy to encourage voluntary immunization in seronegative women and to immunize all postpartum women who are susceptible to rubella virus infection before they leave the hospital.
authors.affiliation: Department of Laboratory Medicine, Fooyin University Hospital, Pingtung, Taiwan.
authors.forename: Ching-Chiang
authors.initials: CC
authors.lastname: Lin
authors.forename: Chun-Yuh
authors.initials: CY
authors.lastname: Yang
authors.forename: Yung-Luen
authors.initials: YL
authors.lastname: Shih
authors.forename: Yang-Yang
authors.initials: YY
authors.lastname: Huang
authors.forename: Tsung-Han
authors.initials: TH
authors.lastname: Yang
authors.forename: Jin-Yuan
authors.initials: JY
authors.lastname: Liang
authors.forename: Chu-Fen
authors.initials: CF
authors.lastname: Chang
authors.forename: Hsiu-Shu
authors.initials: HS
authors.lastname: Hsieh
authors.forename: Yeou-Lih
authors.initials: YL
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D010298:Parity; D011247:Pregnancy; D012411:Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology*; D012412:Rubella virus / Q000276:immunology*; D012574:Schools; D013624:Taiwan; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D012411:Rubella Vaccine
references.citation: Semin Fetal Neonatal Med. 2007 Jun;12(3):182-92
references.pmid: 17337363
references.citation: Int J Epidemiol. 1972 Autumn;1(3):245-52
references.pmid: 4669200
references.citation: Bull World Health Organ. 1997;75(1):69-80
references.pmid: 9141752
references.citation: Clin Vaccine Immunol. 2007 Oct;14(10):1370-1
references.pmid: 17699834
references.citation: Bull World Health Organ. 2008 Feb;86(2):118-25
references.pmid: 18297166
references.citation: Clin Infect Dis. 2006 Nov 1;43 Suppl 3:S133-40
references.pmid: 16998772
references.citation: Vaccine. 1999 Apr 9;17(15-16):2051-8
references.pmid: 10217606
references.citation: Vaccine. 2000 Jul 15;18(27):3106-12
references.pmid: 10856790
references.citation: Rev Infect Dis. 1985 Mar-Apr;7 Suppl 1:S80-5
references.pmid: 4001740
references.citation: Am J Trop Med Hyg. 2010 Jan;82(1):40-4
references.pmid: 20064993
references.citation: JAMA. 2000 Nov 22-29;284(20):2643-7
references.pmid: 11086376
references.citation: Rev Panam Salud Publica. 2003 Nov;14(5):306-15
references.pmid: 14870758
references.citation: Lancet. 1988 Oct 15;2(8616):909
references.pmid: 2902357
references.citation: J Infect Dis. 2003 May 15;187 Suppl 1:S191-7
references.pmid: 12721913
references.citation: BJOG. 2011 May;118(6):706-12
references.pmid: 21385304
references.citation: Am J Trop Med Hyg. 2002 Nov;67(5):549-53
references.pmid: 12479561
references.citation: Public Health. 1989 Sep;103(5):331-5
references.pmid: 2798746
references.citation: Clin Infect Dis. 2006 Nov 1;43 Suppl 3:S123-5
references.pmid: 16998770
references.citation: Vaccine. 1994 Jan;12(1):41-5
references.pmid: 8303939
references.citation: Vaccine. 2009 May 21;27(24):3232-3
references.pmid: 19366581
references.citation: Vaccine. 2006 Mar 24;24(14):2594-601
references.pmid: 16427163
references.citation: J Med Virol. 2007 Jan;79(1):97-103
references.pmid: 17133552